

Global Recombinant Protein Market Report and Forecast 2024-2032

Market Report | 2024-08-07 | 200 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$4999.00
- Five User License \$5999.00
- Corporate License \$6999.00

Report description:

Global Recombinant Protein Market Report and Forecast 2024-2032

The global recombinant protein market was valued at USD 1.9 billion in 2023, driven by the increasing demand for effective drugs to treat chronic diseases across the globe. The market is expected to grow at a CAGR of 11.21% during the forecast period of 2024 and 2032, likely to attain a value of USD 4.94 billion by 2032.

Global Recombinant Protein Market Analysis

The global recombinant protein market has witnessed significant growth over the past few years, driven by advancements in biotechnology and increasing demand for therapeutic proteins. Recombinant proteins are produced through recombinant DNA technology, allowing for the production of proteins in large quantities and with high purity. These proteins are used extensively in various fields, including medical research, diagnostics, and therapeutics, as well as in agricultural and industrial applications.

Market Drivers

One of the primary drivers of the recombinant protein market is the growing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders. Recombinant proteins play a crucial role in the development of biopharmaceuticals that target these conditions, offering more effective and personalised treatment options. The rise in the geriatric population, which is more susceptible to chronic illnesses, further fuels this demand.

Technological advancements in protein expression systems and bioprocessing techniques have significantly enhanced the efficiency and scalability of recombinant protein production. These innovations reduce production costs and improve the quality of the final product, making recombinant proteins more accessible for various applications.

Another critical driver is the increasing investment in research and development (R&D) activities by biopharmaceutical companies and research institutions. This investment is aimed at discovering new therapeutic proteins and improving existing ones, contributing to the expansion of the market.

Challenges

Despite the growth prospects, the recombinant protein market faces several challenges. One of the main challenges is the high cost associated with the production and purification of recombinant proteins. The complexity of the production process and the need for specialised equipment and facilities contribute to these costs, which can limit market growth, especially in developing regions.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Regulatory hurdles also pose a significant challenge. The stringent regulatory requirements for the approval of recombinant protein products can delay their market entry and increase development costs. Companies must navigate these regulations carefully to ensure compliance while maintaining the pace of innovation.

Additionally, the risk of immunogenicity, where the body's immune system reacts against the therapeutic protein, remains a concern. This can lead to adverse effects and reduce the efficacy of the treatment, posing a challenge for the widespread adoption of recombinant protein therapies.

Future Opportunities

The future of the recombinant protein market looks promising, with several opportunities on the horizon. The development of novel expression systems, such as cell-free protein synthesis and synthetic biology approaches, holds the potential to revolutionise recombinant protein production. These technologies offer faster and more cost-effective production methods, which can help overcome current challenges.

The increasing focus on personalised medicine is another significant opportunity. Recombinant proteins can be tailored to individual patients' needs, enhancing the effectiveness of treatments and minimising side effects. This personalised approach is expected to drive the demand for recombinant proteins in the coming years.

Emerging markets, particularly in Asia-Pacific and Latin America, present substantial growth opportunities. These regions are experiencing rising healthcare expenditures and improving biopharmaceutical infrastructure, creating a favourable environment for the expansion of the recombinant protein market.

Furthermore, the growing application of recombinant proteins in the agricultural and industrial sectors, such as in the production of enzymes for biofuels and biodegradable plastics, is expected to open new avenues for market growth.

Global Recombinant Protein Market Trends

The global recombinant protein market is experiencing dynamic growth, driven by technological advancements and increasing demand for personalised therapies. Several key trends are shaping the market's trajectory, offering insights into future developments.

Market Trends:

- Technological Advancements: Innovations in protein expression systems and bioprocessing techniques are enhancing production efficiency and reducing costs, making recombinant proteins more accessible and widely used.
- Personalised Medicine: The shift towards personalised therapies is driving the demand for recombinant proteins, tailored to individual patient needs, improving treatment outcomes and reducing side effects.
- Increasing R&D Investments: Significant investments in research and development are leading to the discovery of new therapeutic proteins and the enhancement of existing ones, fuelling market growth.
- Expansion in Emerging Markets: Regions such as Asia Pacific, Latin America, and the Middle East and Africa are witnessing rapid growth due to improving healthcare infrastructure and increasing biopharmaceutical activities.
- Regulatory Support: Evolving regulatory frameworks and faster approval processes are facilitating the market entry of recombinant protein products, encouraging innovation and market expansion.
- Industrial and Agricultural Applications: The use of recombinant proteins in industrial processes and agriculture, such as enzyme production for biofuels and biodegradable plastics, is opening new avenues for market growth.
- Collaborations and Partnerships: Strategic collaborations between biopharmaceutical companies, research institutions, and biotechnology firms are accelerating the development and commercialisation of recombinant proteins.

Global Recombinant Protein Market Segmentation

Market Breakup by Product Type

- Growth Factor and Cytokines
- Hormone
- Enzyme
- Antibody
- Immune Checkpoint Proteins
- Recombinant Regulatory Proteins
- Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The recombinant protein market, segmented by product type, includes growth factors and cytokines, hormones, enzymes, antibodies, immune checkpoint proteins, recombinant regulatory proteins, and others. Market drivers include rising prevalence of chronic diseases, advancements in biotechnology, and increasing R&D investments. Future growth is expected from innovative production technologies and personalised medicine. Growth factors and cytokines, crucial in cell signalling and therapy, are poised to lead market expansion. Hormones and enzymes are also set for significant growth due to their therapeutic applications. Antibodies and immune checkpoint proteins will drive market growth, particularly in cancer immunotherapy. This segment's dynamic innovation and application potential are key to market growth during the forecast period.

Market Breakup by Application

- Therapeutic
- Research
- Biotechnology Industry

The recombinant protein market, segmented by application, includes therapeutic, research, and biotechnology industry uses. Therapeutic applications, driven by the increasing prevalence of chronic diseases and advancements in personalised medicine, are set to lead market growth. Research applications benefit from rising R&D investments and the need for high-quality proteins in scientific studies. The biotechnology industry, leveraging recombinant proteins for drug development and industrial processes, is poised for significant expansion. Future growth in these segments will be fuelled by technological advancements and innovative production methods, positioning them as key drivers of market growth in the forecast period.

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

The recombinant protein market, segmented by region, includes North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America and Europe lead the market due to advanced healthcare infrastructure, significant R&D investments, and high prevalence of chronic diseases. Asia Pacific is poised for substantial growth, driven by rising healthcare expenditures, improving biopharmaceutical infrastructure, and increasing demand for personalised medicine. Latin America and the Middle East and Africa show potential for growth with expanding healthcare access and growing biopharmaceutical industries. Technological advancements and emerging market opportunities in these regions are expected to drive market growth during the forecast period.

Global Recombinant Protein Market Competitive Landscape

The recombinant protein market is highly competitive, featuring key players such as Abbott, Abcam PLC, Thermo Fisher Scientific, Inc., Bio-Techne Corp., Merck KGaA, Bio-Rad Laboratories, Inc., GeneTex, Inc., Lonza Group SA, F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Sino Biological Inc., TAKARA HOLDINGS INC., Tosoh Corporation, XENOTECH AI Pvt Ltd., and NEW ENGLAND BIOLABS, INC. Common market activities include mergers and acquisitions, which consolidate market positions and expand product portfolios. Extensive research initiatives are undertaken to innovate and enhance product offerings. Companies frequently introduce new products to meet evolving market demands. Strategic partnerships and collaborations are also prevalent, aimed at leveraging combined expertise and expanding market reach. These activities collectively drive the competitive dynamics and growth of the recombinant protein market.

Key Questions Answered in the Report

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- ?□What is the current and future performance of the recombinant protein market?
- ?□What are the main challenges facing the recombinant protein market?
- ?□What are the key drivers of the recombinant protein market?
- ?□What emerging trends are shaping the future of the recombinant protein market?
- ?□How have technological advancements impacted the efficiency and scalability of recombinant protein production?
- ?□What factors are driving the rapid growth of the recombinant protein market in emerging regions?
- ?□How is the shift towards personalised therapies influencing the demand for recombinant proteins?
- ?□How do mergers and acquisitions impact the market positions and product portfolios of companies?

Key Benefits for Stakeholders

- ?□The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global recombinant protein market from 2017-2032.
- ?□The research report provides the latest information on the market drivers, challenges, and opportunities in the recombinant protein market.
- ?□The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- ?□Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the global recombinant protein industry and its attractiveness.
- ?□The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Recombinant Protein Market Overview
 - 3.1 Global Recombinant Protein Market Historical Value (2017-2023)
 - 3.2 Global Recombinant Protein Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
 - 4.1 Key Vendors
 - 4.2 Prospective Leaders
 - 4.3 Niche Leaders
 - 4.4 Disruptors
- 5 Global Recombinant Protein Market Landscape*
 - 5.1 Global Recombinant Protein: Developers Landscape
 - 5.1.1 Analysis by Year of Establishment
 - 5.1.2 Analysis by Company Size
 - 5.1.3 Analysis by Region
 - 5.2 Global Recombinant Protein: Product Landscape
 - 5.2.1 Analysis by Product
 - 5.2.2 Analysis by Vector
 - 5.2.3 Analysis Application
 - 5.2.4 Analysis by Cell type
- 6 Global Recombinant Protein Market Dynamics

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
 - 6.2.1 Strengths
 - 6.2.2 Weaknesses
 - 6.2.3 Opportunities
 - 6.2.4 Threats
- 6.3 PESTEL Analysis
 - 6.3.1 Political
 - 6.3.2 Economic
 - 6.3.3 Social
 - 6.3.4 Technological
 - 6.3.5 Legal
 - 6.3.6 Environment
- 6.4 Porter's Five Forces Model
 - 6.4.1 Bargaining Power of Suppliers
 - 6.4.2 Bargaining Power of Buyers
 - 6.4.3 Threat of New Entrants
 - 6.4.4 Threat of Substitutes
 - 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Recombinant Protein Market Segmentation (2017-2032)
 - 7.1 Global Recombinant Protein Market (2017-2032) by Product Type
 - 7.1.1 Market Overview
 - 7.1.2 Growth Factor and Cytokines
 - 7.1.3 Hormone
 - 7.1.4 Enzyme
 - 7.1.5 Antibody
 - 7.1.6 Immune Checkpoint Proteins
 - 7.1.7 Recombinant Regulatory Proteins
 - 7.1.8 Others
 - 7.2 Global Recombinant Protein Market (2017-2032) by Application
 - 7.2.1 Market Overview
 - 7.2.2 Therapeutic
 - 7.2.3 Research
 - 7.2.4 Biotechnology Industry
 - 7.3 Global Recombinant Protein Market (2017-2032) by Region
 - 7.3.1 Market Overview
 - 7.3.2 North America
 - 7.3.3 Europe
 - 7.3.4 Asia Pacific
 - 7.3.5 Latin America
 - 7.3.6 Middle East and Africa
- 8 North America Recombinant Protein Market (2017-2032)
 - 8.1 North America Recombinant Protein Market (2017-2032) by Product Type

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.1.1 Market Overview
- 8.1.2 Growth Factor and Cytokines
- 8.1.3 Hormone
- 8.1.4 Enzyme
- 8.1.5 Antibody
- 8.1.6 Immune Checkpoint Proteins
- 8.1.7 Recombinant Regulatory Proteins
- 8.1.8 Others
- 8.2 North America Recombinant Protein Market (2017-2032) by Application
 - 8.2.1 Market Overview
 - 8.2.2 Therapeutic
 - 8.2.3 Research
 - 8.2.4 Biotechnology Industry
- 8.3 North America Recombinant Protein Market (2017-2032) by Country
 - 8.3.1 United States of America
 - 8.3.2 Canada
- 9 Europe Recombinant Protein Market (2017-2032)
 - 9.1 Europe Recombinant Protein Market (2017-2032) by Product Type
 - 9.1.1 Market Overview
 - 9.1.2 Growth Factor and Cytokines
 - 9.1.3 Hormone
 - 9.1.4 Enzyme
 - 9.1.5 Antibody
 - 9.1.6 Immune Checkpoint Proteins
 - 9.1.7 Recombinant Regulatory Proteins
 - 9.1.8 Others
 - 9.2 Europe Recombinant Protein Market (2017-2032) by Application
 - 9.2.1 Market Overview
 - 9.2.2 Therapeutic
 - 9.2.3 Research
 - 9.2.4 Biotechnology Industry
 - 9.3 Europe Recombinant Protein Market (2017-2032) by Country
 - 9.3.1 United Kingdom
 - 9.3.2 Germany
 - 9.3.3 France
 - 9.3.4 Italy
 - 9.3.5 Others
- 10 Asia Pacific Recombinant Protein Market (2017-2032)
 - 10.1 Asia Pacific Recombinant Protein Market (2017-2032) by Product Type
 - 10.1.1 Market Overview
 - 10.1.2 Growth Factor and Cytokines
 - 10.1.3 Hormone
 - 10.1.4 Enzyme
 - 10.1.5 Antibody
 - 10.1.6 Immune Checkpoint Proteins
 - 10.1.7 Recombinant Regulatory Proteins
 - 10.1.8 Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.2 Asia Pacific Recombinant Protein Market (2017-2032) by Application

10.2.1 Market Overview

10.2.2 Therapeutic

10.2.3 Research

10.2.4 Biotechnology Industry

10.3 Asia Pacific Recombinant Protein Market (2017-2032) by Country

10.3.1 China

10.3.2 Japan

10.3.3 India

10.3.4 ASEAN

10.3.5 Australia

10.3.6 Others

11 Latin America Recombinant Protein Market (2017-2032)

11.1 Latin America Recombinant Protein Market (2017-2032) by Product Type

11.1.1 Market Overview

11.1.2 Growth Factor and Cytokines

11.1.3 Hormone

11.1.4 Enzyme

11.1.5 Antibody

11.1.6 Immune Checkpoint Proteins

11.1.7 Recombinant Regulatory Proteins

11.1.8 Others

11.2 Latin America Recombinant Protein Market (2017-2032) by Application

11.2.1 Market Overview

11.2.2 Therapeutic

11.2.3 Research

11.2.4 Biotechnology Industry

11.3 Latin America Recombinant Protein Market (2017-2032) by Country

11.3.1 Brazil

11.3.2 Argentina

11.3.3 Mexico

11.3.4 Others

12 Middle East and Africa Recombinant Protein Market (2017-2032)

12.1 Middle East and Africa Recombinant Protein Market (2017-2032) by Product Type

12.1.1 Market Overview

12.1.2 Growth Factor and Cytokines

12.1.3 Hormone

12.1.4 Enzyme

12.1.5 Antibody

12.1.6 Immune Checkpoint Proteins

12.1.7 Recombinant Regulatory Proteins

12.1.8 Others

12.2 Middle East and Africa Recombinant Protein Market (2017-2032) by Application

12.2.1 Market Overview

12.2.2 Therapeutic

12.2.3 Research

12.2.4 Biotechnology Industry

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.3 Middle East and Africa Recombinant Protein Market (2017-2032) by Country
 - 12.3.1 Saudi Arabia
 - 12.3.2 United Arab Emirates
 - 12.3.3 Nigeria
 - 12.3.4 South Africa
 - 12.3.5 Others
- 13 Regulatory Framework
 - 13.1 Regulatory Overview
 - 13.2 US FDA
 - 13.3 EU EMA
 - 13.4 INDIA CDSCO
 - 13.5 JAPAN PMDA
 - 13.6 Others
- 14 Patent Analysis
 - 14.1 Analysis by Type of Patent
 - 14.2 Analysis by Publication Year
 - 14.3 Analysis by Issuing Authority
 - 14.4 Analysis by Patent Age
 - 14.5 Analysis by CPC Analysis
 - 14.6 Analysis by Patent Valuation
 - 14.7 Analysis by Key Players
- 15 Clinical Trial Analysis
 - 15.1 Analysis by Trial Registration Year
 - 15.2 Analysis by Trial Status
 - 15.3 Analysis by Trial Phase
 - 15.4 Analysis by Therapeutic Area
 - 15.5 Analysis by Geography
- 16 Grant Analysis
 - 16.1 Analysis by Year
 - 16.2 Analysis by Amount Awarded
 - 16.3 Analysis by Issuing Authority
 - 16.4 Analysis by Grant Product
 - 16.5 Analysis by Funding Institute
 - 16.6 Analysis by Departments
 - 16.7 Analysis by Recipient Organization
- 17 Funding and Investment Analysis
 - 17.1 Analysis by Funding Instances
 - 17.2 Analysis by Type of Funding
 - 17.3 Analysis by Funding Amount
 - 17.4 Analysis by Leading Players
 - 17.5 Analysis by Leading Investors
 - 17.6 Analysis by Geography
- 18 Strategic Initiative
 - 18.1 Analysis by Partnership Instances
 - 18.2 Analysis by Type of Partnership
 - 18.3 Analysis by Leading Players
 - 18.4 Analysis by Geography

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 19 Supplier Landscape
 - 19.1 Market Share Analysis, By Region (Top 5 Companies)
 - 19.1.1 Market Share Analysis: Global
 - 19.1.2 Market Share Analysis: North America
 - 19.1.3 Market Share Analysis: Europe
 - 19.1.4 Market Share Analysis: Asia-Pacific
 - 19.1.5 Market Share Analysis: Others
 - 19.2 Abbott
 - 19.2.1 Financial Analysis
 - 19.2.2 Product Portfolio
 - 19.2.3 Demographic Reach and Achievements
 - 19.2.4 Mergers and Acquisitions
 - 19.2.5 Certifications
 - 19.3 Abcam PLC
 - 19.3.1 Financial Analysis
 - 19.3.2 Product Portfolio
 - 19.3.3 Demographic Reach and Achievements
 - 19.3.4 Mergers and Acquisitions
 - 19.3.5 Certifications
 - 19.4 Thermo Fisher Scientific, Inc .
 - 19.4.1 Financial Analysis
 - 19.4.2 Product Portfolio
 - 19.4.3 Demographic Reach and Achievements
 - 19.4.4 Mergers and Acquisitions
 - 19.4.5 Certifications
 - 19.5 Bio-Techne Corp .
 - 19.5.1 Financial Analysis
 - 19.5.2 Product Portfolio
 - 19.5.3 Demographic Reach and Achievements
 - 19.5.4 Mergers and Acquisitions
 - 19.5.5 Certifications
 - 19.6 Merck KGaA
 - 19.6.1 Financial Analysis
 - 19.6.2 Product Portfolio
 - 19.6.3 Demographic Reach and Achievements
 - 19.6.4 Mergers and Acquisitions
 - 19.6.5 Certifications
 - 19.7 Bio-Rad Laboratories, Inc .
 - 19.7.1 Financial Analysis
 - 19.7.2 Product Portfolio
 - 19.7.3 Demographic Reach and Achievements
 - 19.7.4 Mergers and Acquisitions
 - 19.7.5 Certifications
 - 19.8 GeneTex, Inc
 - 19.8.1 Financial Analysis
 - 19.8.2 Product Portfolio
 - 19.8.3 Demographic Reach and Achievements

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 19.8.4 Mergers and Acquisitions
- 19.8.5 Certifications
- 19.9 Lonza Group SA
 - 19.9.1 Financial Analysis
 - 19.9.2 Product Portfolio
 - 19.9.3 Demographic Reach and Achievements
 - 19.9.4 Mergers and Acquisitions
 - 19.9.5 Certifications
- 19.10 F. Hoffmann-La Roche Ltd .
 - 19.10.1 Financial Analysis
 - 19.10.2 Product Portfolio
 - 19.10.3 Demographic Reach and Achievements
 - 19.10.4 Mergers and Acquisitions
 - 19.10.5 Certifications
- 19.11 PerkinElmer Inc .
 - 19.11.1 Financial Analysis
 - 19.11.2 Product Portfolio
 - 19.11.3 Demographic
 - 19.11.4 Mergers and Acquisitions
 - 19.11.5 Certifications
- 19.12 Sino Biological Inc .
 - 19.12.1 Financial Analysis
 - 19.12.2 Product Portfolio
 - 19.12.3 Demographic Reach and Achievements
 - 19.12.4 Mergers and Acquisitions
 - 19.12.5 Certifications
- 19.13 TAKARA HOLDINGS INC .
 - 19.13.1 Financial Analysis
 - 19.13.2 Product Portfolio
 - 19.13.3 Demographic Reach and Achievements
 - 19.13.4 Mergers and Acquisitions
 - 19.13.5 Certifications
- 19.14 Tosoh Corporation
 - 19.14.1 Financial Analysis
 - 19.14.2 Product Portfolio
 - 19.14.3 Demographic Reach and Achievements
 - 19.14.4 Mergers and Acquisitions
 - 19.14.5 Certifications
- 19.15 XENOTECH AI Pvt Ltd .
 - 19.15.1 Financial Analysis
 - 19.15.2 Product Portfolio
 - 19.15.3 Demographic Reach and Achievements
 - 19.15.4 Mergers and Acquisitions
 - 19.15.5 Certifications
- 19.16 NEW ENGLAND BIOLABS, INC
 - 19.16.1 Financial Analysis
 - 19.16.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

19.16.3 Demographic Reach and Achievements

19.16.4 Mergers and Acquisitions

19.16.5 Certifications

20 Recombinant Protein Market - Distribution Model (Additional Insight)

20.1 Overview

20.2 Potential Distributors

20.3 Key Parameters for Distribution Partner Assessment

21 Key Opinion Leaders (KOL) Insights (Additional Insight)

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

**The supplier list is not exhaustive, moreover we can provide analysis of companies as per custom request.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Recombinant Protein Market Report and Forecast 2024-2032

Market Report | 2024-08-07 | 200 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4999.00
	Five User License	\$5999.00
	Corporate License	\$6999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-05"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com